抗体産生の世界市場：産生プロセス、エンドユーザー、市場予測...市場調査レポートについてご紹介

1 Introduction (Page No. – 21)
1.1 Objectives of the Study
1.2 Antibody Production Market Definition
1.3 Antibody Production Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 24)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Key Industry Insights
2.2.2.2 Key Data From Primary Sources
2.2.2.3 Key Insights From Primary Sources
2.3 Antibody Production Market Size Estimation Methodology
2.4 Antibody Production Market Forecast Methodology
2.5 Antibody Production Market Data Validation and Triangulation
2.6 Assumptions for the Study

3 Executive Summary (Page No. – 33)
3.1 Introduction
3.2 Current and Future Scenario
3.3 Conclusion

4 Premium Insights (Page No. – 37)
4.1 Antibody Production Market Overview
4.2 Antibody Production Market Size, By Process, 2016 vs 2021
4.3 Antibody Production Market Size, By End User, 2016 vs 2021

5 Market Overview (Page No. – 40)
5.1 Introduction of Antibody Production Market
5.2 Antibody Production Market Segmentation
5.3 Antibody Production Market Dynamics
5.3.1 Drivers
5.3.1.1 U.S. Fda Clearance of Therapeutic Mabs
5.3.1.2 Increasing Adoption of Targeted Immunotherapy
5.3.1.3 Increasing R&D Expenditure in Pharmaceutical and Biotechnological Companies
5.3.1.4 Rising Number of Fast Track and Orphan Drug Designations
5.3.2 Restraints
5.3.2.1 Cost Constraints Related to the Adoption of Membrane Filters
5.3.3 Opportunities
5.3.3.1 Rising Demand for Protein Therapeutics
5.3.3.2 Increasing Risk of Infectious Diseases
5.3.3.3 Patent Expiry of Blockbuster Mabs
5.3.4 Challenges
5.3.4.1 High Costs of Primary Antibodies

6 Antibody Production Market, By Process (Page No. – 48)
6.1 Introduction
6.2 Upstream Processing
6.2.1 Bioreactors
6.2.1.1 Large-Scale Bioreactors
6.2.1.2 Single-Use Bioreactors (SUBS)
6.2.2 Consumables
6.2.2.1 Media
6.2.2.2 Reagents and Buffers
6.3 Downstream Processing
6.3.1 Chromatography Instruments
6.3.2 Chromatography Resins
6.3.2.1 Affinity Chromatography Resins
6.4 Ion Exchange (IEX) Chromatography Resins
6.5 Hydrophobic Interaction Chromatography (HIC) Resins
6.6 Multimodal Chromatography Resins
6.7 Filtration
6.7.1 Filtration Systems
6.7.2 Filtration Consumables and Accessories

7 Antibody Production Market, By End User (Page No. – 94)
7.1 Introduction
7.1.1 Pharmaceutical and Biotechnology Companies
7.1.2 Diagnostic Laboratories
7.1.3 Research Institutes

8 Global Antibody Production Market, By Region (Page No. – 99)
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.1.1 Rising Cancer Incidence in the U.S.
8.2.1.2 Government Funding for Medical Research
8.2.1.3 Conferences, Symposia, and Seminars on Bioprocessing Technologies
8.2.2 Canada
8.2.2.1 Government Initiatives to Promote Research
8.2.2.2 Need for Quality Cancer Treatment
8.2.2.3 Regulatory Approvals and Authorization for Use of Mabs
8.3 Europe
8.3.1 Germany
8.3.1.1 Increasing Focus on R&D
8.3.1.2 Government Funding
8.3.2 U.K.
8.3.2.1 Flourishing Biotechnology and Biopharmaceutical Industry
8.3.3 France
8.3.3.1 Growing Presence of Chromatography Players in France
8.3.4 Rest of Europe (RoE)
8.3.4.1 Investments and Funding for Life Sciences to Bolster the Antibody Production Market
8.4 Asia-Pacific
8.4.1 Japan
8.4.1.1 Growing Biopharmaceutical Sector and Rise in Geriatric Population
8.4.2 China
8.4.2.1 Increasing Government and Private-Sector Investments in China’s Life Sciences Market
8.4.2.2 Outsourcing of Clinical Research Activities to China
8.4.3 India
8.4.3.1 Increasing Government Initiatives and Growing Pharmaceutical Industry in India
8.4.3.2 Development of Bioclusters to Boost India’s Biotechnology Industry
8.4.4 Rest of Asia-Pacific
8.4.4.1 Funding From the Australian Government for Scientific Research and Innovation
8.4.4.2 Infrastructural Development in Vietnam
8.4.4.3 Rising Pharmaceutical and Biotechnology R&D Activities in Korea
8.4.4.4 Government Support for Strong Academic and Commercial R&D Activities in Taiwan
8.5 Rest of the World
8.5.1 Latin America
8.5.1.1 Pharmaceutical, Biotechnology, and Research Industries in Brazil to Bolster the Market
8.5.1.2 Mexico, the Production Hub for Global Pharmaceutical Companies
8.5.2 Middle East and Africa (MEA)
8.5.2.1 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and Uae
8.5.2.2 Increasing Focus on Africa By Pharmaceutical Companies

9 Competitive Landscape (Page No. – 162)
9.1 Antibody Production Market: Overview
9.2 Antibody Production Market: Strategic Overview
9.3 Competitive Situation and Trends
9.3.1 New Product Launches
9.3.2 Expansions
9.3.3 Agreements, Alliances, Partnerships, and Collaborations
9.3.4 Mergers and Acquisitions
9.3.5 Other Strategies

10 Company Profiles (Page No. – 170)
(Company at A Glance, Business Overview, Products Offered, Key Strategy, Recent Developments, SWOT Analysis & MnM View)*
10.1 Introduction
10.2 GE Healthcare (A SUBSidiary of General Electric Company)
10.3 Merck KGAA
10.4 Thermo Fisher Scientific, Inc.
10.5 Sartorius AG
10.6 Pall Corporation (Acquired By Danaher Corporation)
10.7 Sigma-Aldrich Corporation (Acquired By Merck KGAA)
10.8 Eppendorf AG
10.9 Cellab GmbH
10.10 Integra Biosciences AG
10.11 Fibercell Systems Inc.

*Details on Company at A Glance, Recent Financials, Products Offered, Strategies & Insights, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.

11 Appendix (Page No. – 198)
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Other Developments (2013–2016)
11.3.1 GE Healthcare
11.3.2 Merck KGAA
11.3.3 Thermo Fisher Scientific, Inc.
11.3.4 Sartorius AG
11.3.5 Sigma-Aldrich Corporation (Acquired By Merck KGAA)
11.3.6 Eppendorf AG
11.3.7 Integra Biosciences Group
11.4 Knowledge Store: Marketsandmarkets’ SUBScription Portal
11.5 Introducing RT: Real-Time Market Intelligence
11.6 Available Customizations
11.7 Related Reports